Chapter 4 Principles of Protein Misfolding

Progress in Nucleic Acid Research and Molecular Biology

Volumn 84, Issue , 2008, Pages 115-160

  Ramirez Alvarado, Marina ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58049217041     PISSN: 00796603     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6603(08)00404-2     Document Type: Review

References (151)

1. Clark P.L. Protein folding in the cell: Reshaping the folding funnel. Trends Biochem. Sci. 29 (2004) 527-534
2. Hulmes D.J. Building collagen molecules, fibrils, and suprafibrillar structures. J. Struct. Biol. 137 (2002) 2-10
3. Lomas D.A., Evans D.L., Stone S.R., Chang W.S., and Carrell R.W. Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochemistry 32 (1993) 500-508
4. King J., Haase-Pettingell C., Robinson A.S., Speed M., and Mitraki A. Thermolabile folding intermediates: Inclusion body precursors and chaperonin substrates. Faseb J. 10 (1996) 57-66
5. Wetzel R. For protein misassembly, it's the "I" decade. Cell 86 (1996) 699-702
6. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., and Dobson C.M. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. USA 96 (1999) 3590-3594
7. Ramirez-Alvarado M., Merkel J.S., and Regan L. A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc. Natl. Acad. Sci. USA 97 (2000) 8979-8984
8. Dill K.A., and Chan H.S. From levinthal to pathways to funnels. Nat. Struct. Biol. 4 (1997) 10-19
9. Locker C.R., and Hernandez R. A minimalist model protein with multiple folding funnels. Proc. Natl. Acad. Sci. USA 98 (2001) 9074-9079
10. Mitraki A., Fane B., Haase-Pettingell C., Sturtevant J., and King J. Global suppression of protein folding defects and inclusion body formation. Science 253 (1991) 54-58
11. Hammarstrom P., Schneider F., and Kelly J.W. Trans-suppression of misfolding in an amyloid disease. Science 293 (2001) 2459-2462
12. Wigley W.C., Corboy M.J., Cutler T.D., Thibodeau P.H., Oldan J., Lee M.G., Rizo J., Hunt J.F., and Thomas P.J. A protein sequence that can encode native structure by disfavoring alternate conformations. Nat. Struct. Biol. 9 (2002) 381-388
13. Richardson J.S., and Richardson D.C. Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc. Natl. Acad. Sci. USA 99 (2002) 2754-2759
14. Hartl F.U., and Hayer-Hartl M. Molecular chaperones in the cytosol: From nascent chain to folded protein. Science 295 (2002) 1852-1858
15. Dobson C.M., and Karplus M. The fundamentals of protein folding: Bringing together theory and experiment. Curr. Opin. Struct. Biol. 9 (1999) 92-101
16. Patzelt H., Rudiger S., Brehmer D., Kramer G., Vorderwulbecke S., Schaffitzel E., Waitz A., Hesterkamp T., Dong L., Schneider-Mergener J., Bukau B., and Deuerling E. Binding specificity of Escherichia coli trigger factor. Proc. Natl. Acad. Sci. USA 98 (2001) 14244-14249
17. Hartl F.U. Molecular chaperones in cellular protein folding. Nature 381 (1996) 571-579
18. Pfund C., Lopez-Hoyo N., Ziegelhoffer T., Schilke B.A., Lopez-Buesa P., Walter W.A., Wiedmann M., and Craig E.A. The molecular chaperone Ssb from Saccharomyces cerevisiae is a component of the ribosome-nascent chain complex. EMBO J. 17 (1998) 3981-3989
19. Gautschi M., Lilie H., Funfschilling U., Mun A., Ross S., Lithgow T., Rucknagel P., and Rospert S. RAC, a stable ribosome-associated complex in yeast formed by the DnaK-DnaJ homologs Ssz1p and zuotin. Proc. Natl. Acad. Sci. USA 98 (2001) 3762-3767
20. Gautschi M., Mun A., Ross S., and Rospert S. A functional chaperone triad on the yeast ribosome. Proc. Natl. Acad. Sci. USA 99 (2002) 4209-4214
21. Erbse A., Mayer M.P., and Bukau B. Mechanism of substrate recognition by Hsp70 chaperones. Biochem. Soc. Trans. 32 (2004) 617-621
22. Leroux M.R., Fandrich M., Klunker D., Siegers K., Lupas A.N., Brown J.R., Schiebel E., Dobson C.M., and Hartl F.U. MtGimC, a novel archaeal chaperone related to the eukaryotic chaperonin cofactor GimC/prefoldin. EMBO J. 18 (1999) 6730-6743
23. Sigler P.B., Xu Z., Rye H.S., Burston S.G., Fenton W.A., and Horwich A.L. Structure and function in GroEL-mediated protein folding. Annu. Rev. Biochem. 67 (1998) 581-608
24. Farr G.W., Furtak K., Rowland M.B., Ranson N.A., Saibil H.R., Kirchhausen T., and Horwich A.L. Multivalent binding of nonnative substrate proteins by the chaperonin GroEL. Cell 100 (2000) 561-573
25. Ellis R.J. Molecular chaperones: Inside and outside the Anfinsen cage. Curr. Biol. 11 (2001) R1038-R1040
26. Kerner M.J., Naylor D.J., Ishihama Y., Maier T., Chang H.C., Stines A.P., Georgopoulos C., Frishman D., Hayer-Hartl M., Mann M., and Hartl F.U. Proteome-wide analysis of chaperonin-dependent protein folding in Escherichia coli. Cell 122 (2005) 209-220
27. Brinker A., Pfeifer G., Kerner M.J., Naylor D.J., Hartl F.U., and Hayer-Hartl M. Dual function of protein confinement in chaperonin-assisted protein folding. Cell 107 (2001) 223-233
28. Shtilerman M., Lorimer G.H., and Englander S.W. Chaperonin function: Folding by forced unfolding. Science 284 (1999) 822-825
29. Chen J., Walter S., Horwich A.L., and Smith D.L. Folding of malate dehydrogenase inside the GroEL-GroES cavity. Nat. Struct. Biol. 8 (2001) 721-728
30. Chaudhuri T.K., Farr G.W., Fenton W.A., Rospert S., and Horwich A.L. GroEL/GroES-mediated folding of a protein too large to be encapsulated. Cell 107 (2001) 235-246
31. Paul S., Singh C., Mishra S., and Chaudhuri T.K. The 69 kDa Escherichia coli maltodextrin glucosidase does not get encapsulated underneath GroES and folds through trans mechanism during GroEL/GroES-assisted folding. Faseb J. 21 (2007) 2874-2885
32. Young J.C., Agashe V.R., Siegers K., and Hartl F.U. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell. Biol. 5 (2004) 781-791
33. Farr G.W., Scharl E.C., Schumacher R.J., Sondek S., and Horwich A.L. Chaperonin-mediated folding in the eukaryotic cytosol proceeds through rounds of release of native and nonnative forms. Cell. 89 (1997) 927-937
34. Won K.A., Schumacher R.J., Farr G.W., Horwich A.L., and Reed S.I. Maturation of human cyclin E requires the function of eukaryotic chaperonin CCT. Mol. Cell. Biol. 18 (1998) 7584-7589
35. Feldman D.E., Thulasiraman V., Ferreyra R.G., and Frydman J. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol. Cell. 4 (1999) 1051-1061
36. Frydman J. Folding of newly translated proteins in vivo: The role of molecular chaperones. Annu. Rev. Biochem. 70 (2001) 603-647
37. Netzer W.J., and Hartl F.U. Recombination of protein domains facilitated by co-translational folding in eukaryotes. Nature 388 (1997) 343-349
38. Ewalt K.L., Hendrick J.P., Houry W.A., and Hartl F.U. In vivo observation of polypeptide flux through the bacterial chaperonin system. Cell 90 (1997) 491-500
39. Evans M.S., Ugrinov K.G., Frese M.A., and Clark P.L. Homogeneous stalled ribosome nascent chain complexes produced in vivo or in vitro. Nat. Methods 2 (2005) 757-762
40. Siegers K., Waldmann T., Leroux M.R., Grein K., Shevchenko A., Schiebel E., and Hartl F.U. Compartmentation of protein folding in vivo: Sequestration of non-native polypeptide by the chaperonin-GimC system. Embo J. 18 (1999) 75-84
41. Luders J., Demand J., and Hohfeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J. Biol. Chem. 275 (2000) 4613-4617
42. Connell P., Ballinger C.A., Jiang J., Wu Y., Thompson L.J., Hohfeld J., and Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell. Biol. 3 (2001) 93-96
43. Demand J., Alberti S., Patterson C., and Hohfeld J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr. Biol. 11 (2001) 1569-1577
44. van Anken E., and Braakman I. Endoplasmic reticulum stress and the making of a professional secretory cell. Crit. Rev. Biochem. Mol. Biol. 40 (2005) 269-283
45. Meusser B., Hirsch C., Jarosch E., and Sommer T. ERAD: The long road to destruction. Nat. Cell. Biol. 7 (2005) 766-772
46. Matlack K.E., Mothes W., and Rapoport T.A. Protein translocation: Tunnel vision. Cell 92 (1998) 381-390
47. Bukau B., Weissman J., and Horwich A. Molecular chaperones and protein quality control. Cell 125 (2006) 443-451
48. Schroder M., and Kaufman R.J. The mammalian unfolded protein response. Annu. Rev. Biochem. 74 (2005) 739-789
49. Jensen T.J., Loo M.A., Pind S., Williams D.B., Goldberg A.L., and Riordan J.R. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83 (1995) 129-135
50. Ward C.L., Omura S., and Kopito R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83 (1995) 121-127
51. Sommer T., and Jentsch S. A protein translocation defect linked to ubiquitin conjugation at the endoplasmic reticulum. Nature 365 (1993) 176-179
52. Biederer T., Volkwein C., and Sommer T. Degradation of subunits of the Sec61p complex, an integral component of the ER membrane, by the ubiquitin-proteasome pathway. EMBO J. 15 (1996) 2069-2076
53. Hiller M.M., Finger A., Schweiger M., and Wolf D.H. ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science 273 (1996) 1725-1728
54. Biederer T., Volkwein C., and Sommer T. Role of Cue1p in ubiquitination and degradation at the ER surface. Science 278 (1997) 1806-1809
55. Wiertz E.J., Tortorella D., Bogyo M., Yu J., Mothes W., Jones T.R., Rapoport T.A., and Ploegh H.L. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384 (1996) 432-438
56. Kimata Y., Oikawa D., Shimizu Y., Ishiwata-Kimata Y., and Kohno K. A role for BiP as an adjustor for the endoplasmic reticulum stress-sensing protein Ire1. J. Cell. Biol. 167 (2004) 445-456
57. Credle J.J., Finer-Moore J.S., Papa F.R., Stroud R.M., and Walter P. On the mechanism of sensing unfolded protein in the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA 102 (2005) 18773-18784
58. Vashist S., and Ng D.T. Misfolded proteins are sorted by a sequential checkpoint mechanism of ER quality control. J. Cell. Biol. 165 (2004) 41-52
59. Nishikawa S., Brodsky J.L., and Nakatsukasa K. Roles of molecular chaperones in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). J. Biochem. 137 (2005) 551-555
60. Sekijima Y., Wiseman R.L., Matteson J., Hammarstrom P., Miller S.R., Sawkar A.R., Balch W.E., and Kelly J.W. The biological and chemical basis for tissue-selective amyloid disease. Cell 121 (2005) 73-85
61. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
62. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95 (1998) 6469-6473
63. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V.M., Trojanowski J.Q., Mann D., and Iwatsubo T. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277 (2002) 49071-49076
64. Tofaris G.K., Razzaq A., Ghetti B., Lilley K.S., and Spillantini M.G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278 (2003) 44405-44411
65. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., Diep L., Keim P.S., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281 (2006) 29739-29752
66. Liani E., Eyal A., Avraham E., Shemer R., Szargel R., Berg D., Bornemann A., Riess O., Ross C.A., Rott R., and Engelender S. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc. Natl. Acad. Sci. USA 101 (2004) 5500-5505
67. Rott R., Szargel R., Haskin J., Shani V., Shainskaya A., Manov I., Liani E., Avraham E., and Engelender S. Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem. 283 (2008) 3316-3328
68. Lee J.T., Wheeler T.C., Li L., and Chin L.S. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum. Mol. Genet. 17 (2008) 906-917
69. Conway K.A., Harper J.D., and Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4 (1998) 1318-1320
70. Engelender S. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. Autophagy 4 (2008) 372-374
71. McNaught K.S., and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297 (2001) 191-194
72. Aharon-Peretz J., Rosenbaum H., and Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351 (2004) 1972-1977
73. Settembre C., Fraldi A., Jahreiss L., Spampanato C., Venturi C., Medina D., de Pablo R., Tacchetti C., Rubinsztein D.C., and Ballabio A. A block of autophagy in lysosomal storage disorders. Hum. Mol. Genet. 17 (2008) 119-129
74. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., and Greene L.A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21 (2001) 9549-9560
75. Gidalevitz T., Ben-Zvi A., Ho K.H., Brignull H.R., and Morimoto R.I. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311 (2006) 1471-1474
76. Wiseman R.L., Powers E.T., Buxbaum J.N., Kelly J.W., and Balch W.E. An adaptable standard for protein export from the endoplasmic reticulum. Cell 131 (2007) 809-821
77. Balch W.E., Morimoto R.I., Dillin A., and Kelly J.W. Adapting proteostasis for disease intervention. Science 319 (2008) 916-919
78. Sunde M., Serpell L.C., Bartlam M., Fraser P.E., Pepys M.B., and Blake C.C. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273 (1997) 729-739
79. Buxbaum J.N. Diseases of protein conformation: What do in vitro experiments tell us about in vivo diseases?. Trends Biochem. Sci. 28 (2003) 585-592
80. Ross C.A., and Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 Suppl. (2004) S10-S17
81. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., and Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
82. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 (1999) 8876-8884
83. Reixach N., Deechongkit S., Jiang X., Kelly J.W., and Buxbaum J.N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. USA 101 (2004) 2817-2822
84. Pokrzywa M., Dacklin I., Hultmark D., and Lundgren E. Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. Eur. J. Neurosci. 26 (2007) 913-924
85. Brenner D.A., Jain M., Pimentel D.R., Wang B., Connors L.H., Skinner M., Apstein C.S., and Liao R. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ. Res. 94 (2004) 1008-1010
86. Keeling J., Teng J., and Herrera G.A. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab. Invest. 84 (2004) 1322-1338
87. Trinkaus-Randall V., Walsh M.T., Steeves S., Monis G., Connors L.H., and Skinner M. Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am. J. Pathol. 166 (2005) 197-208
88. Monis G.F., Schultz C., Ren R., Eberhard J., Costello C., Connors L., Skinner M., and Trinkaus-Randall V. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. Am. J. Pathol. 169 (2006) 1939-1952
89. Kelly J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8 (1998) 101-106
90. Lai Z., Colon W., and Kelly J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35 (1996) 6470-6482
91. Torrent J., Balny C., and Lange R. High pressure modulates amyloid formation. Protein Pept. Lett. 13 (2006) 271-277
92. Kyle R.A., and Greipp P.R. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo. Clin. Proc. 58 (1983) 665-683
93. Kyle R.A., Linos A., Beard C.M., Linke R.P., Gertz M.A., O'Fallon W.M., and Kurland L.T. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79 (1992) 1817-1822
94. Olsen K.E., Sletten K., and Westermark P. Extended analysis of AL-amyloid protein from abdominal wall subcutaneous fat biopsy: Kappa IV immunoglobulin light chain. Biochem. Biophys. Research Comm. 245 (1998) 713-716
95. Buxbaum J. Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture. J. Clin. Invest. 78 (1986) 798-806
96. Bergen III H.R., Abraham R.S., Johnson K.L., Bradwell A.R., and Naylor S. Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation. Biomed. Chromatogr. 18 (2004) 191-201
97. Branden C., and Tooze J. Introduction to Protein Structure (1999), 2nd edn, Garland, New York
98. Epp O., Lattman E.E., Schiffer M., Huber R., and Palm W. The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution. Biochemistry 14 (1975) 4943-4952
99. Huang D.B., Chang C.H., Ainsworth C., Johnson G., Solomon A., Stevens F.J., and Schiffer M. Variable domain structure of kappaIV human light chain Len: High homology to the murine light chian McPC603. Mol. Immunol. 34 (1997) 1291
100. Pokkuluri P.R., Huang D.B., Raffen R., Cai X., Johnson G., Wilkins Stevens P., Stevens F.J., and Schiffer M. A domain flip as a result of a single amino acid substitution. Structure (Camb) 6 (1998) 1067-1073
101. Pokkuluri P.R., Solomon A., Weiss D.T., Stevens F.J., and Schiffer M. Tertiary structure of human lambda 6 light chains. Amyloid 6 (1999) 165-171
102. Alim M.A., Yamaki S., Hossain M.S., Takeda K., Kozima M., Izumi T., Takashi I., and Shinoda T. Structural relationship of kappa-type light chains with AL amyloidosis: Multiple deletions found in a VkappaIV protein. Clin. Exp. Immunol. 118 (1999) 344-348
103. Wall J., Gupta V., Wilkerson M., Schell M., Loris R., Adams P., Solomon A., Stevens F.J., and Dealwis C. Structural basis of light chain amyloidogenicity: Comparison of thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vl6 proteins. J. Mol. Recog. 17 (2004) 323-331
104. Schormann N., Murrell J.R., Liepnieks J.J., and Benson M.D. Tertiary structure of an amyloid immunoglobulin light chain protein: A proposed model for amyloid fibril formation. Proc. Natl. Acad. Sci. USA 92 (1995) 9490-9494
105. Bourne P.C., Ramsland P.A., Shan L., Fan Z.C., DeWitt C.R., Shultz B.B., Terzyan S.S., Moomaw C.R., Slaughter C.A., Guddat L.W., and Edmundson A.B. Three-dimensional structure of an immunoglobulin light-chain dimer with amyloidogenic properties. Acta. Crystallogr. D. Biol. Crystallogr. 58 (2002) 815-823
106. Padlan E.A. Anatomy of the antibody molecule. Mol. Immunol. 31 (1994) 169-217
107. Klein M., Kortan C., Kells D.I., and Dorrington K.J. Equilibrium and kinetic aspects of the interaction of isolated variable and constant domains of light chain with the Fd' fragment of immunoglobulin G. Biochemistry 18 (1979) 1473-1481
108. Alexandru I., Kells D.I., Dorrington K.J., and Klein M. Non-covalent association of heavy and light chains of human immunoglobulin G: Studies using light chain labelled with a fluorescent probe. Mol. Immunol. 17 (1980) 1351-1363
109. Wall J., Schell M., Murphy C., Hrncic R., Stevens F.J., and Solomon A. Thermodynamic instability of human lambda 6 light chains: Correlation with fibrillogenicity. Biochemistry 38 (1999) 14101-14108
110. Kim Y., Wall J.S., Meyer J., Murphy C., Randolph T.W., Manning M.C., Solomon A., and Carpenter J.F. Thermodynamic modulation of light chain amyloid fibril formation. J. Biol. Chem. 275 (2000) 1570-1574
111. Hurle M.R., Helms L.R., Li L., Chan W., and Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc. Natl. Acad. Sci. USA 91 (1994) 5446-5450
112. Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv. Protein Chem. 50 (1997) 183-242
113. Stevens, F.J., Weiss, D.T., Solomon, A. Structural bases of light chain-related pathology In: M. Zanetti, and J. D. Capra, (Eds.), The antibodies, Vol. 5. Harwood Academic Publishers, Langehorne, PA, pp. 175-208
114. Stevens F.J. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 7 (2000) 200-211
115. Dul J.L., and Argon Y. A single amino acid substitution in the variable region of the light chain specifically blocks immunoglobulin secretion. Proc. Natl. Acad. Sci. USA 87 (1990) 8135-8139
116. Morrison S.L., and Sharff M.D. Heavy chain-producing variants of a mouse myeloma cell line. J. Immun. 114 (1975) 655-659
117. Kohler G. Immunoglobulin chain loss in hybridoma lines. Proc. Natl. Acad. Sci. USA 77 (1980) 2197-2199
118. Haas I.G., and Wabl M.R. Immunoglobulin heavy chain toxicity in plasma cells is neutralized by fusion by pre B-cells. Proc. Natl. Acad. Sci. USA 81 (1984) 7185-7188
119. Chou C.L., and Morrison S.L. An insertion-deletion even in murine immunoglobulin kappa gene resembles mutations at heavy-chain disease loci. Somat. Cell. Mol. Genet. 19 (1993) 131-139
120. Buxbaum J.N. Abnormal immunoglobulin synthesis in monoclonal immunoglobulin light chain and light and heavy chain deposition disease. Amyloid 8 (2001) 84-93
121. Cogne M., Silvain C., Khamlichi A.A., and Preud'homme J.L. Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood 79 (1992) 2181-2195
122. Gertz M.A., Lacy M.Q., and Dispenzieri A. Amyloidosis. Hematol. Oncol. Clin. North Am. 13 (1999) 1211-1233
123. Gertz M.A., and Kyle R.A. Prognostic value of urinary protein in primary systemic amyloidosis (AL). Am. J. Clin. Pathol. 94 (1990) 313-317
124. Kyle R.A., and Gertz M.A. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin. Hematol. 32 (1995) 45-59
125. Gertz M.A., and Kyle R.A. Hepatic amyloidosis: Clinical appraisal in 77 patients. Hepatology 25 (1997) 118-121
126. Sezer O., Eucker J., Schmid P., and Possinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann. Hematol. 79 (2000) 1-6
127. Dispenzieri A., Lacy M.Q., Katzmann J.A., Rajkumar S.V., Abraham R.S., Hayman S.R., Kumar S.K., Clark R., Kyle R.A., Litzow M.R., Inwards D.J., Ansell S.M., et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107 (2006) 3378-3383
128. Abraham R.S., Geyer S.M., Price-Troska T.L., Allmer C., Kyle R.A., Gertz M.A., and Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101 (2003) 3801-3808
129. Comenzo R.L., Wally J., Kica G., Murray J., Ericsson T., Skinner M., and Zhang Y. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: Association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br. J. Haematol. 106 (1999) 744-751
130. Khan M.F., and Falk R.H. Amyloidosis. Postgrad. Med. J. 77 (2001) 686-693
131. O'Nuallain B., Allen A., Kennel S.J., Weiss D.T., Solomon A., and Wall J.S. Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry 46 (2007) 1240-1247
132. Davis P.D., Raffen R., Dul L.J., Vogen M.S., Williamson K.E., Stevens J.F., and Argon Y. Inhibition of amyloid fiber assembly by both BiP and its target peptide. Immunity 13 (2000) 433-442
133. Dul J.L., Davis D.P., Williamson E.K., Stevens F.J., and Argon Y. Hsp70 and antifibrillogenic peptides promote degradation and inhibit intracellular aggregation of amyloidogenic light chains. J. Cell. Biol. 152 (2001) 705-715
134. Baden E.M., Owen B.A., Peterson F.C., Volkman B.F., Ramirez-Alvarado M., and Thompson J.R. Altered dimer interface decreases stability in an amyloidogenic protein. J. Biol. Chem. 283 (2008) 15853-15860
135. Qin Z., Hu D., Zhu M., and Fink A.L. Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation. Biochemistry 46 (2007) 3521-3531
136. Koo E.H., Lansbury P.T., and Kelly J.W. Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. USA 96 (1999) 9989-9990
137. Sacchettini J.C., and Kelly J.W. Therapeutic strategies for human amyloid diseases. Nat. Rev. Drug. Discovery 1 (2002) 267-275
138. Stevens F.J., and Argon Y. Pathogenic light chains and the B-cell repertoire. Immunol. Today 20 (1999) 451-457
139. Ramirez-Alvarado M., and Regan L. Does the location of a mutation determine the ability to form amyloid fibrils?. J. Mol. Biol. 323 (2002) 17-22
140. Khurana R., Souillac P.O., Coats A.C., Minert L.J., Ionescu-Zanetti C., Carter S.A., Solomon A., and Fink A.L. A model for amyloid formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding. Amyloid 10 (2003) 97-109
141. Khurana R., Gillespie J.R., Talapatra A., Minert L.J., Ionescu-Zanetti C., Millett I., and Fink A.L. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 40 (2001) 3525-3535
142. Wall J., Murphy C.L., and Solomon A. In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol. 309 (1999) 204-217
143. Ramirez-Alvarado M., Cocco M., and Regan L. Mutations in the B1 domain of protein G that delay the onset of amyloid fibril formation in vitro. Protein Sci. 12 (2003) 567-576
144. McLaughlin R.W., De Stigter J.K., Sikkink L.A., Baden E.M., and Ramirez-Alvarado M. The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein. Protein Sci. 15 (2006) 1710-1722
145. Kim Y.-S., Randolph T.W., Stevens F.J., and Carpenter J.F. Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein. J. Biol. Chem. 277 (2002) 27240-27246
146. Davis D.P., Gallo G., Vogen S.M., Dul J.L., Sciarretta K.L., Kumar A., Raffen R., Stevens F.J., and Argon Y. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain. J. Mol. Biol. 313 (2001) 1021-1034
147. Zhu M., Han S., Zhou F., Carter S.A., and Fink A.L. Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy. J. Biol. Chem. 279 (2004) 24452-24459
148. Zhu M., Souillac P.O., Ionescu-Zanetti C., Carter S.A., and Fink A.L. Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 277 (2002) 50914-50922
149. Dobson C.M. Protein folding and misfolding. Nature 426 (2003) 884-890
150. Souillac P.O., Uversky V.N., Millett I.S., Khurana R., Doniach S., and Fink A.L. Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off- pathway oligomer at acidic pH. J. Biol. Chem. 277 (2002) 12666-12679
151. Del Pozo Yauner L., Ortiz E., Sanchez R., Sanchez-Lopez R., Guereca L., Murphy C.L., Allen A., Wall J.S., Fernandez-Velasco D.A., Solomon A., and Becerril B. Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains. Proteins 72 (2008) 684-692